sibutramine has been researched along with Metabolic Syndrome in 14 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two." | 5.12 | Impact of weight loss on the metabolic syndrome. ( Berkowitz, RI; Cato, RK; Phelan, S; Rothman, R; Sarwer, DB; Wadden, TA; Womble, LG, 2007) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| "Obesity is associated with significant increase in cardiovascular risk." | 2.43 | The obesity epidemic and its cardiovascular consequences. ( Behn, A; Ur, E, 2006) |
| "Overweight and obesity are major factors contributing to the development of type 2 diabetes mellitus (DM) and cardiovascular disease (CVD)." | 1.35 | The endocannabinoid system as a target for obesity treatment. ( Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (85.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aronne, LJ | 2 |
| Pagotto, U | 1 |
| Foster, GD | 1 |
| Davis, SN | 1 |
| Madsen, AN | 1 |
| Hansen, G | 1 |
| Paulsen, SJ | 1 |
| Lykkegaard, K | 1 |
| Tang-Christensen, M | 1 |
| Hansen, HS | 1 |
| Levin, BE | 1 |
| Larsen, PJ | 1 |
| Knudsen, LB | 1 |
| Fosgerau, K | 1 |
| Vrang, N | 1 |
| Nagayama, D | 1 |
| Shirai, K | 1 |
| Cuppini, A | 1 |
| Matteini, P | 1 |
| Blackburn, GL | 1 |
| Waltman, BA | 1 |
| Behn, A | 1 |
| Ur, E | 1 |
| Pi-Sunyer, FX | 1 |
| Fujioka, K | 1 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Phelan, S | 1 |
| Wadden, TA | 1 |
| Berkowitz, RI | 1 |
| Sarwer, DB | 1 |
| Womble, LG | 1 |
| Cato, RK | 1 |
| Rothman, R | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Lee, JW | 1 |
| Lee, HR | 1 |
| Shim, JY | 1 |
| Im, JA | 1 |
| Lee, DC | 1 |
9 reviews available for sibutramine and Metabolic Syndrome
| Article | Year |
|---|---|
[Sibutramine and its adequate usage].
Topics: Appetite Depressants; Cyclobutanes; Humans; Metabolic Syndrome; Obesity | 2011 |
[Obesity and metabolic syndrome: clinical and therapeutic review].
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2005 |
Pharmacotherapy to reduce visceral fat.
Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdom | 2005 |
The obesity epidemic and its cardiovascular consequences.
Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Metabolic syndrome treatment strategies.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; O | 2006 |
Therapeutic options for modifying cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hypoglycem | 2007 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
2 trials available for sibutramine and Metabolic Syndrome
| Article | Year |
|---|---|
Impact of weight loss on the metabolic syndrome.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Female; Humans; Life Style; Male; Metabolic Syndrom | 2007 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
3 other studies available for sibutramine and Metabolic Syndrome
| Article | Year |
|---|---|
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabin | 2008 |
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
Topics: Analysis of Variance; Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diet; Disease Mode | 2010 |
Abdominal visceral fat reduction is associated with favorable changes of serum retinol binding protein-4 in nondiabetic subjects.
Topics: Adiposity; Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insulin Resist | 2008 |